The novel findings of the study were as follows: (a) AURKA modulates pre-mRNA alternative splicing in breast cancer (Fig. 1); (b) Aberrant splicing of RBM4 and GOLGA4 is closely related to breast cancer development (Fig. 2); (c) AURKA cooperates with different splicing factors to co-regulate cancer-related RNA splicing (Fig. 3); (d) The AURKA-YBX1/hnRNPK complex is associated with adverse outcome in breast cancer (Fig. 4); (e) Small molecule inhibitors of AURKA nuclear translocation prevent RBM4 and GOLGA4 aberrant splicing in breast cancer cells (Fig. 5). Here, HNRNPK is linked to breast carcinoma.